Peroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring

Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E514-24. doi: 10.1152/ajpendo.00008.2009. Epub 2009 Jun 2.

Abstract

The effect of early intervention with a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist on skeletal muscle GLUT4 translocation and insulin signaling was examined in intrauterine (IUGR) and postnatal (PNGR) growth-restricted pregestational female rat offspring. Rosiglitazone [11 mumol/day provided from postnatal day (PN)21 to PN60] improved skeletal muscle insulin sensitivity and GLUT4 translocation in prenatal nutrient restriction [50% calories from embryonic day (e)11 to e21; IUGR] with (IUGR+PNGR) and without (IUGR) postnatal nutrient restriction (50% calories from PN1 to PN21; PNGR) similar to that of control (ad libitum feeds throughout; Con) (n = 6 each). This was accomplished by diminished basal and improved insulin-responsive GLUT4 association with the plasma membrane in IUGR, IUGR+PNGR, and PNGR mimicking that in Con (P < 0.005). While no change in p85-phosphatidylinositol 3-kinase (PI3-K) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was observed, a decrease in protein tyrosine phosphatase 1B (PTP1B; P < 0.0002) and SH2-containing protein tyrosine phosphatase 2 (SHP2; P < 0.05) contributing to the rosiglitazone-induced insulin sensitivity was seen only in IUGR+PNGR. In contrast, an increase in phosphorylated 5'-adenosine monophosphate kinase (pAMPK; P < 0.04) and insulin responsiveness of phosphorylated phosphoinositide-dependent protein kinase-1 (pPDK1; P < 0.05), pAkt (P < 0.01), and particularly pPKCzeta (P < 0.0001) and its corresponding enzyme activity (P < 0.005) were observed in all four experimental groups. We conclude that early introduction of PPARgamma agonist improved skeletal muscle activation of AMPK and insulin signaling, resulting in insulin-independent AMPK and insulin-responsive GLUT4 association with plasma membranes in IUGR, IUGR+PNGR, and PNGR adult offspring, similar to that of Con. These findings support a role for insulin sensitizers in preventing the subsequent development of gestational or type 2 diabetes mellitus in intrauterine and postnatal growth-restricted offspring.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Algorithms
  • Animals
  • Drug Evaluation, Preclinical
  • Female
  • Fetal Growth Retardation / metabolism*
  • Fetal Growth Retardation / pathology
  • Fetal Growth Retardation / physiopathology
  • Fetal Growth Retardation / rehabilitation
  • Glucose Transporter Type 4 / metabolism
  • Growth / drug effects
  • Hypoglycemic Agents / pharmacology
  • Insulin / metabolism*
  • Models, Biological
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / metabolism
  • PPAR gamma / agonists*
  • Pregnancy
  • Prenatal Exposure Delayed Effects / metabolism*
  • Prenatal Exposure Delayed Effects / physiopathology
  • Prenatal Exposure Delayed Effects / rehabilitation
  • Rats
  • Rosiglitazone
  • Signal Transduction / drug effects
  • Thiazolidinediones / pharmacology*

Substances

  • Glucose Transporter Type 4
  • Hypoglycemic Agents
  • Insulin
  • PPAR gamma
  • Slc2a4 protein, rat
  • Thiazolidinediones
  • Rosiglitazone